SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/14/21 Lab Corp. of America Holdings 8-K:8,9 5/12/21 13:399K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 28K 2: EX-1.1 Underwriting Agreement or Conflict Minerals Report HTML 130K 3: EX-5.1 Opinion of Counsel re: Legality HTML 14K 4: EX-99.1 Miscellaneous Exhibit HTML 11K 9: R1 Document and Entity Information HTML 46K 11: XML IDEA XML File -- Filing Summary XML 13K 8: XML XBRL Instance -- d467972d8k_htm XML 14K 10: EXCEL IDEA Workbook of Financial Reports XLSX 6K 6: EX-101.LAB XBRL Labels -- lh-20210512_lab XML 54K 7: EX-101.PRE XBRL Presentations -- lh-20210512_pre XML 34K 5: EX-101.SCH XBRL Schema -- lh-20210512 XSD 13K 12: JSON XBRL Instance as JSON Data -- MetaLinks 12± 19K 13: ZIP XBRL Zipped Folder -- 0001193125-21-160766-xbrl Zip 44K
EX-99.1 |
Exhibit 99.1
FOR IMMEDIATE RELEASE
Labcorp Contacts:
Media: Christopher Allman-Bradshaw — 336-436-8263
Investors: Chas Cook — 336-436-5076
LABCORP PRICES $500,000,000 IN 1.550% SENIOR NOTES DUE 2026 AND $500,000,000 IN 2.700% SENIOR NOTES DUE 2031
BURLINGTON, N.C., May 12, 2021 — Labcorp (NYSE: LH) (“Labcorp”) announced today that it has priced its offering of $1,000,000,000 in senior notes. The offering consists of two tranches: $500,000,000 aggregate principal amount of 1.550% Senior Notes due 2026 (the “2026 Notes”) and $500,000,000 aggregate principal amount of 2.700% Senior Notes due 2031 (the “2031 Notes” and, together with the 2026 Notes, the “Notes”). The Notes will bear interest from May 26, 2021, payable semi-annually on June 1 and December 1, commencing on December 1, 2021. The closing of the offering is expected to occur on May 26, 2021, subject to the satisfaction of customary closing conditions. The Notes will be senior unsecured obligations and will rank equally with Labcorp’s existing and future senior unsecured debt.
Labcorp expects to use the net proceeds of the Notes offering to redeem, prior to maturity, its outstanding 3.20% Senior Notes due Feb. 1, 2022 and 3.75% Senior Notes due Aug. 23, 2022.
The joint book-running managers for the offering are BofA Securities, KeyBanc Capital Markets, and Wells Fargo Securities. The offering will be made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-234633) filed with the Securities and Exchange Commission (the “SEC”) on Nov. 12, 2019. A copy of the prospectus and related prospectus supplement may be obtained without charge from the SEC. Alternatively, a copy of the prospectus and related prospectus supplement may be obtained from BofA Securities by calling toll-free 1-800-294-1322, from KeyBanc Capital Markets by calling toll-free 1-866-227-6479, or from Wells Fargo Securities by calling toll-free 1-800-645-3751.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the Notes or any other securities, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The offering of these securities may be made only by means of the prospectus supplement and the accompanying prospectus.
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements including statements about the proposed offering of the Notes and use of proceeds therefrom. Each of the forward-looking statements is subject to change based on various important factors, including the risk that the offering may not be successful. As a result, readers are cautioned not to place undue reliance on any of Labcorp’s forward-looking statements. Labcorp has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks, and uncertainties that could affect operating and financial results is included in Labcorp’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in Labcorp’s other filings with the SEC.
# # #
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
8/23/22 | ||||
2/1/22 | SC 13G/A | |||
12/1/21 | ||||
5/26/21 | 8-K | |||
Filed as of: | 5/14/21 | 424B5, 8-K | ||
Filed on: | 5/13/21 | 424B5, FWP | ||
For Period end: | 5/12/21 | 424B5, 8-K, DEF 14A, FWP | ||
11/12/19 | S-3ASR | |||
List all Filings |